BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 36414694)

  • 1. EEG-based grading of immune effector cell-associated neurotoxicity syndrome.
    Jones DK; Eckhardt CA; Sun H; Tesh RA; Malik P; Quadri S; Firme MS; van Sleuwen M; Jain A; Fan Z; Jing J; Ge W; Nascimento FA; Sheikh IS; Jacobson C; Frigault M; Kimchi EY; Cash SS; Lee JW; Dietrich J; Westover MB
    Sci Rep; 2022 Nov; 12(1):20011. PubMed ID: 36414694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
    Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
    Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment.
    Gu T; Hu K; Si X; Hu Y; Huang H
    WIREs Mech Dis; 2022 Nov; 14(6):e1576. PubMed ID: 35871757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy.
    Sterner RC; Sterner RM
    Front Immunol; 2022; 13():879608. PubMed ID: 36081506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy.
    Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH
    Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Neurotoxicity after Chimeric Antigen Receptor (CAR) T Cell Infusion without Deterioration in the Immune Effector Cell Encephalopathy (ICE) Score.
    Herr MM; Chen GL; Ross M; Jacobson H; McKenzie R; Markel L; Balderman SR; Ho CM; Hahn T; McCarthy PL
    Biol Blood Marrow Transplant; 2020 Nov; 26(11):e271-e274. PubMed ID: 32736009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EEG before chimeric antigen receptor T-cell therapy and early after onset of immune effector cell-associated neurotoxicity syndrome.
    Hernani R; Aiko M; Victorio R; Benzaquén A; Pérez A; Piñana JL; Hernández-Boluda JC; Amat P; Pastor-Galán I; Remigia MJ; Ferrer-Lores B; Micó M; Carbonell N; Ferreres J; Blasco-Cortés ML; Santonja JM; Dosdá R; Estellés R; Campos S; Martínez-Ciarpaglini C; Ferrández-Izquierdo A; Goterris R; Gómez M; Teruel A; Saus A; Ortiz A; Morello D; Martí E; Carretero C; Calabuig M; Tormo M; Terol MJ; Cases P; Solano C
    Clin Neurophysiol; 2024 Apr; 163():132-142. PubMed ID: 38733703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurotoxicity Biology and Management.
    Danish H; Santomasso BD
    Cancer J; 2021 Mar-Apr 01; 27(2):126-133. PubMed ID: 33750072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment.
    Schoeberl F; Tiedt S; Schmitt A; Blumenberg V; Karschnia P; Burbano VG; Bücklein VL; Rejeski K; Schmidt C; Busch G; von Bergwelt-Baildon M; Tonn JC; Schmitt M; Subklewe M; von Baumgarten L
    Blood Adv; 2022 May; 6(10):3022-3026. PubMed ID: 35042236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frontal Intermittent Rhythmic Delta Activity Is a Useful Diagnostic Tool of Neurotoxicity After CAR T-Cell Infusion.
    Huby S; Gelisse P; Tudesq JJ; Labauge P; Duflos C; Cartron G; Gallerand MA; Platon L; Badiou S; Lamure S; Menjot de Champfleur N; Ayrignac X; Taieb G
    Neurol Neuroimmunol Neuroinflamm; 2023 Jul; 10(4):. PubMed ID: 37059470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor t-cell therapy.
    Amidi Y; Eckhardt CA; Quadri SA; Malik P; Firme MS; Jones DK; Jain A; Danish HH; Rubin DB; Jacobson CA; Cash SS; Lee JW; Dietrich J; Westover MB
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36450377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multifocal demyelinating leukoencephalopathy and oligodendroglial lineage cell loss with immune effector cell-associated neurotoxicity syndrome (ICANS) following CD19 CAR T-cell therapy for mantle cell lymphoma.
    Nie EH; Ahmadian SS; Bharadwaj SN; Acosta-Alvarez L; Threlkeld ZD; Frank MJ; Miklos DB; Monje M; Scott BJ; Vogel H
    J Neuropathol Exp Neurol; 2023 Jan; 82(2):160-168. PubMed ID: 36592076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma.
    Nie EH; Su YJ; Baird JH; Agarwal N; Bharadwaj S; Weng WK; Smith M; Dahiya S; Han MH; Dunn JE; Kipp LB; Miklos DB; Scott BJ; Frank MJ
    Blood Adv; 2024 Mar; 8(6):1474-1486. PubMed ID: 38295285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma.
    Strati P; Nastoupil LJ; Westin J; Fayad LE; Ahmed S; Fowler NH; Hagemeister FB; Lee HJ; Iyer SP; Nair R; Parmar S; Rodriguez MA; Samaniego F; Steiner RE; Wang M; Pinnix CC; Adkins S; Claussen CM; Martinez CS; Hawkins MC; Johnson NA; Singh P; Mistry HE; Horowitz S; George S; Feng L; Kebriaei P; Shpall EJ; Neelapu SS; Tummala S; Chi TL
    Blood Adv; 2020 Aug; 4(16):3943-3951. PubMed ID: 32822484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicities following CAR-T therapy for hematological malignancies.
    Hernani R; Benzaquén A; Solano C
    Cancer Treat Rev; 2022 Dec; 111():102479. PubMed ID: 36308910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS).
    Wehrli M; Gallagher K; Chen YB; Leick MB; McAfee SL; El-Jawahri AR; DeFilipp Z; Horick N; O'Donnell P; Spitzer T; Dey B; Cook D; Trailor M; Lindell K; Maus MV; Frigault MJ
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34996813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of diagnostic investigations in the management of CAR T-cell-associated neurotoxicity.
    Mauget M; Lemercier S; Quelven Q; Maamar A; Lhomme F; De Guibert S; Houot R; Manson G
    Blood Adv; 2024 May; 8(10):2491-2498. PubMed ID: 38501964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies.
    Yang C; Nguyen J; Yen Y
    J Biomed Sci; 2023 Oct; 30(1):89. PubMed ID: 37864230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokines in CAR T Cell-Associated Neurotoxicity.
    Gust J; Ponce R; Liles WC; Garden GA; Turtle CJ
    Front Immunol; 2020; 11():577027. PubMed ID: 33391257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Automated detection of immune effector cell-associated neurotoxicity syndrome via quantitative EEG.
    Eckhardt CA; Sun H; Malik P; Quadri S; Santana Firme M; Jones DK; van Sleuwen M; Jain A; Fan Z; Jing J; Ge W; Danish HH; Jacobson CA; Rubin DB; Kimchi EY; Cash SS; Frigault MJ; Lee JW; Dietrich J; Westover MB
    Ann Clin Transl Neurol; 2023 Oct; 10(10):1776-1789. PubMed ID: 37545104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.